Joseph Juan

Joseph Juan

Auto-generated profile, based on publicly available information

Joseph Juan

Nurix Therapeutics

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 September 2022 in Cancer Research
Verified
Journal Article
Open access
PDF file
AVAria Vaishnavi
Aria Vaishnavi
JJJoseph Juan
Joseph Juan
MJMaebh Jacob
Maebh Jacob
CSChristopher Stehn
Christopher Stehn
EGEric E. Gardner
Eric E. Gardner
MMMartin McMahon
Martin McMahon
Mutationally activated BRAF is detected in approximately 7% of human lung adenocarcinomas, with BRAFT1799A serving as a predictive biomarker for treatment of patients with FDA-approved inhibitors of BRAFV600E oncoprotein signaling. In genetically engineered mouse (GEM) models, expression of BRAFV600E in the lung epithelium initiates growth of benign lung tumors that, without additional genetic alterations, rarely progress to malignant lung adenocarcinoma. To identify genes that cooperate with BRAFV600E for malignant progression, we used Sleeping Beauty–mediated transposon mutagenesis, which dramatically accelerated the emergence of lethal lung cancers. Among the genes identified was Rbms3, which encodes an RNA-binding protein previously implicated as a putative tumor suppressor. Silencing of RBMS3 via CRISPR/Cas9 gene editing promoted growth of BRAFV600E lung organoids and promoted development of malignant lung cancers with a distinct micropapillary architecture in BRAFV600E and EGFRL858R GEM models. BRAFV600E/RBMS3Null lung tumors displayed elevated expression of Ctnnb1, Ccnd1, Axin2, Lgr5, and c-Myc mRNAs, suggesting that RBMS3 silencing elevates signaling through the WNT/β-catenin signaling axis. Although RBMS3 silencing rendered BRAFV600E-driven lung tumors resistant to the effects of dabrafenib plus trametinib, the tumors were sensitive to inhibition of porcupine, an acyltransferase of WNT ligands necessary for their secretion. Analysis of The Cancer Genome Atlas patient samples revealed that chromosome 3p24, which encompasses RBMS3, is frequently lost in non–small cell lung cancer and correlates with poor prognosis. Collectively, these data reveal the role of RBMS3 as a lung cancer suppressor and suggest that RBMS3 silencing may contribute to malignant NSCLC progression. Significance: Loss of RBMS3 cooperates with BRAFV600E to induce lung tumorigenesis, providing a deeper understanding of the molecular mechanisms underlying mutant BRAF-driven lung cancer and potential strategies to more effectively target this disease.

24 January 2026 in bioRxiv
Verified
Preprint
Open access
PDF file
GSGajewski Stefan
Gajewski Stefan
TATaherbhoy M. Asad
Taherbhoy M. Asad
BKBoyle Kathleen
Boyle Kathleen
GJGosling Jennifa
Gosling Jennifa
PJPerkins Jilliane
Perkins Jilliane
CFCohen Frederick
Cohen Frederick
CBL-B is a RING-type E3 ubiquitin ligase that acts as a critical negative regulator of T-cell activation. It promotes T-cell anergy and suppresses immune responses through ubiquitin-mediated control of signaling proteins at the immunological synapse. T cells deficient in CBL-B activity lose their dependence on CD28 co-stimulation, exhibit heightened activation and increased cytokine production, and fail to re-establish anergy. In addition, mice deficient in CBL-B activity reject tumors. Together, this cellular mechanism and in vivo phenotype suggest inhibition of CBL-B may be a viable immuno-oncology therapeutic strategy. Here, we report the rational design and execution of a high-throughput screen (HTS) to identify small molecule inhibitors of CBL-B. This campaign led to the discovery of a scaffold that inhibits CBL-B E3 ligase activity with micromolar potency. Structural characterization revealed an intramolecular glue mechanism, in which the compound stabilizes the closed state of CBL-B, preventing phosphorylation of a tyrosine residue that is critical for activation and E2 binding. Iterative structure–activity optimization yielded compounds with nanomolar activity that enhanced T-cell activation and cytokine secretion in primary human T cells and suppressed tumor growth in a syngeneic colorectal mouse model. Together, these studies validate the biological rationale for pharmacological CBL-B inhibition and enabled the de novo discovery of intramolecular CBL-B glue inhibitors. This work culminated in the identification of NX-1607, a first-in-class oral CBL-B inhibitor now in clinical development for cancer immunotherapy.

31 March 2023
Verified
Other
Open access
AVAria Vaishnavi
Aria Vaishnavi
JJJoseph Juan
Joseph Juan
MJMaebh Jacob
Maebh Jacob
CSChristopher Stehn
Christopher Stehn
EGEric E. Gardner
Eric E. Gardner
MMMartin McMahon
Martin McMahon
Supplementary Data from Transposon Mutagenesis Reveals RBMS3 Silencing as a Promoter of Malignant Progression of BRAFV600E-Driven Lung Tumorigenesis

31 March 2023
Verified
Other
Open access
AVAria Vaishnavi
Aria Vaishnavi
JJJoseph Juan
Joseph Juan
MJMaebh Jacob
Maebh Jacob
CSChristopher Stehn
Christopher Stehn
EGEric E. Gardner
Eric E. Gardner
MMMartin McMahon
Martin McMahon
Supplementary Data from Transposon Mutagenesis Reveals RBMS3 Silencing as a Promoter of Malignant Progression of BRAFV600E-Driven Lung Tumorigenesis

31 March 2023
Verified
Other
Open access
AVAria Vaishnavi
Aria Vaishnavi
JJJoseph Juan
Joseph Juan
MJMaebh Jacob
Maebh Jacob
CSChristopher Stehn
Christopher Stehn
EGEric E. Gardner
Eric E. Gardner
MMMartin McMahon
Martin McMahon
Supplementary Data from Transposon Mutagenesis Reveals RBMS3 Silencing as a Promoter of Malignant Progression of BRAFV600E-Driven Lung Tumorigenesis

31 March 2023
Verified
Other
Open access
AVAria Vaishnavi
Aria Vaishnavi
JJJoseph Juan
Joseph Juan
MJMaebh Jacob
Maebh Jacob
CSChristopher Stehn
Christopher Stehn
EGEric E. Gardner
Eric E. Gardner
MMMartin McMahon
Martin McMahon
Supplementary Data from Transposon Mutagenesis Reveals RBMS3 Silencing as a Promoter of Malignant Progression of BRAFV600E-Driven Lung Tumorigenesis